Therapeutic potential of functional selectivity in the treatment of heart failure

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Therapeutic potential of functional selectivity in the treatment of heart failure. / Christensen, Gitte Lund; Aplin, Mark; Hansen, Jakob Lerche.

In: Trends in Cardiovascular Medicine, Vol. 20, No. 7, 10.2010, p. 221-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Christensen, GL, Aplin, M & Hansen, JL 2010, 'Therapeutic potential of functional selectivity in the treatment of heart failure', Trends in Cardiovascular Medicine, vol. 20, no. 7, pp. 221-7. https://doi.org/10.1016/j.tcm.2011.11.005

APA

Christensen, G. L., Aplin, M., & Hansen, J. L. (2010). Therapeutic potential of functional selectivity in the treatment of heart failure. Trends in Cardiovascular Medicine, 20(7), 221-7. https://doi.org/10.1016/j.tcm.2011.11.005

Vancouver

Christensen GL, Aplin M, Hansen JL. Therapeutic potential of functional selectivity in the treatment of heart failure. Trends in Cardiovascular Medicine. 2010 Oct;20(7):221-7. https://doi.org/10.1016/j.tcm.2011.11.005

Author

Christensen, Gitte Lund ; Aplin, Mark ; Hansen, Jakob Lerche. / Therapeutic potential of functional selectivity in the treatment of heart failure. In: Trends in Cardiovascular Medicine. 2010 ; Vol. 20, No. 7. pp. 221-7.

Bibtex

@article{73d8728702ec407183cd959d7a6a1db7,
title = "Therapeutic potential of functional selectivity in the treatment of heart failure",
abstract = "Adrenergic and angiotensin receptors are prominent targets in pharmacological alleviation of cardiac remodeling and heart failure, but their use is associated with cardiodepressant side effects. Recent advances in our understanding of seven transmembrane receptor signaling show that it is possible to design ligands with {"}functional selectivity,{"} acting as agonists on certain signaling pathways while antagonizing others. This represents a major pharmaceutical opportunity to separate desired from adverse effects governed by the same receptor. Accordingly, functionally selective ligands are currently pursued as next-generation drugs for superior treatment of heart failure.",
keywords = "Adrenergic beta-Agonists, Adrenergic beta-Antagonists, Angiotensin II Type 1 Receptor Blockers, Animals, Heart Failure, Humans, Ligands, Mice, Mice, Transgenic, Receptor, Angiotensin, Type 1, Receptors, Adrenergic, beta, Signal Transduction",
author = "Christensen, {Gitte Lund} and Mark Aplin and Hansen, {Jakob Lerche}",
note = "Copyright {\textcopyright} 2010 Elsevier Inc. All rights reserved.",
year = "2010",
month = oct,
doi = "10.1016/j.tcm.2011.11.005",
language = "English",
volume = "20",
pages = "221--7",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier",
number = "7",

}

RIS

TY - JOUR

T1 - Therapeutic potential of functional selectivity in the treatment of heart failure

AU - Christensen, Gitte Lund

AU - Aplin, Mark

AU - Hansen, Jakob Lerche

N1 - Copyright © 2010 Elsevier Inc. All rights reserved.

PY - 2010/10

Y1 - 2010/10

N2 - Adrenergic and angiotensin receptors are prominent targets in pharmacological alleviation of cardiac remodeling and heart failure, but their use is associated with cardiodepressant side effects. Recent advances in our understanding of seven transmembrane receptor signaling show that it is possible to design ligands with "functional selectivity," acting as agonists on certain signaling pathways while antagonizing others. This represents a major pharmaceutical opportunity to separate desired from adverse effects governed by the same receptor. Accordingly, functionally selective ligands are currently pursued as next-generation drugs for superior treatment of heart failure.

AB - Adrenergic and angiotensin receptors are prominent targets in pharmacological alleviation of cardiac remodeling and heart failure, but their use is associated with cardiodepressant side effects. Recent advances in our understanding of seven transmembrane receptor signaling show that it is possible to design ligands with "functional selectivity," acting as agonists on certain signaling pathways while antagonizing others. This represents a major pharmaceutical opportunity to separate desired from adverse effects governed by the same receptor. Accordingly, functionally selective ligands are currently pursued as next-generation drugs for superior treatment of heart failure.

KW - Adrenergic beta-Agonists

KW - Adrenergic beta-Antagonists

KW - Angiotensin II Type 1 Receptor Blockers

KW - Animals

KW - Heart Failure

KW - Humans

KW - Ligands

KW - Mice

KW - Mice, Transgenic

KW - Receptor, Angiotensin, Type 1

KW - Receptors, Adrenergic, beta

KW - Signal Transduction

U2 - 10.1016/j.tcm.2011.11.005

DO - 10.1016/j.tcm.2011.11.005

M3 - Journal article

C2 - 22293022

VL - 20

SP - 221

EP - 227

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 7

ER -

ID: 46394520